ProQR Therapeutics Management

Management Kriterienprüfungen 4/4

ProQR Therapeutics CEO ist Daniel de Boer , ernannt in Feb 2012, hat eine Amtszeit von 12.75 Jahren. Die jährliche Gesamtvergütung beträgt €2.44M , bestehend aus 21.5% Gehalt und 78.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.68% der Aktien des Unternehmens, im Wert von $2.66M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.8 Jahre bzw. 6.2 Jahre.

Wichtige Informationen

Daniel de Boer

Geschäftsführender

€2.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts21.5%
Amtszeit als Geschäftsführer12.8yrs
Eigentum des Geschäftsführers0.7%
Durchschnittliche Amtszeit des Managements4.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6.2yrs

Jüngste Management Updates

Recent updates

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

Oct 23
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Jul 15
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

May 29
Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Apr 03
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Nov 28
Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Jul 30
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17
Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10
Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13
It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08
If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01
Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01
A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Daniel de Boer im Vergleich zu den Einnahmen von ProQR Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-€24m

Jun 30 2024n/an/a

-€22m

Mar 31 2024n/an/a

-€27m

Dec 31 2023€2m€524k

-€28m

Sep 30 2023n/an/a

-€37m

Jun 30 2023n/an/a

-€54m

Mar 31 2023n/an/a

-€59m

Dec 31 2022€2m€504k

-€64m

Sep 30 2022n/an/a

-€69m

Jun 30 2022n/an/a

-€61m

Mar 31 2022n/an/a

-€63m

Dec 31 2021€2m€449k

-€61m

Sep 30 2021n/an/a

-€57m

Jun 30 2021n/an/a

-€55m

Mar 31 2021n/an/a

-€43m

Dec 31 2020€3m€449k

-€47m

Sep 30 2020n/an/a

-€52m

Jun 30 2020n/an/a

-€51m

Mar 31 2020n/an/a

-€58m

Dec 31 2019€2m€449k

-€56m

Sep 30 2019n/an/a

-€51m

Jun 30 2019n/an/a

-€45m

Mar 31 2019n/an/a

-€40m

Dec 31 2018€1m€445k

-€37m

Sep 30 2018n/an/a

-€35m

Jun 30 2018n/an/a

-€40m

Mar 31 2018n/an/a

-€44m

Dec 31 2017€1m€353k

-€44m

Vergütung im Vergleich zum Markt: DanielDie Gesamtvergütung ($USD2.61M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD2.32M).

Entschädigung vs. Einkommen: DanielDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.


Geschäftsführer

Daniel de Boer (41 yo)

12.8yrs

Amtszeit

€2,439,000

Vergütung

Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Daniel de Boer
Founder12.8yrs€2.44m0.68%
$ 2.7m
Domenico Valerio
Founder & Independent Member of Supervisory Boardno data€150.00k0.41%
$ 1.6m
Rene Beukema
Chief Corporate Development Officer2.4yrs€1.31m0.45%
$ 1.7m
Gerard Platenburg
Co-Founder12.8yrs€34.00kkeine Daten
Jurriaan Dekkers
Chief Financial Officer2yrskeine Datenkeine Daten
Sheila Sponselee
Chief People & Operations Officer4.8yrskeine Datenkeine Daten
Sarah Kiely
Vice President of Investor Relations & Corporate Communicationsno datakeine Datenkeine Daten
Sandra van der Kolk
Junior Financial Controllerno datakeine Datenkeine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: PRQRDas Führungsteam des Unternehmens gilt als erfahren (4.8 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Domenico Valerio
Founder & Independent Member of Supervisory Board10.8yrs€150.00k0.41%
$ 1.6m
Alison Lawton
Independent Member of Supervisory Board10.2yrs€126.00k0%
$ 0
Phillip Zamore
Member of Scientific Advisory Board7.4yrskeine Datenkeine Daten
Theresa Heggie
Supervisory Board Member1.5yrs€271.00k0.026%
$ 99.9k
James Shannon
Chairman of the Board of Directors & Chairman of Scientific Advisory Board4.3yrs€132.00k0.060%
$ 232.0k
Bart Filius
Member of the Board of Directors5.8yrs€127.00k0%
$ 0
Martin Maier
Supervisory Board Member & Member of Scientific Advisory Board4.3yrskeine Datenkeine Daten
Peter Beal
Member Scientific Advisory Board6.6yrskeine Datenkeine Daten
Yi-Tao Yu
Member of Scientific Advisory Board6.5yrskeine Datenkeine Daten
Begona Carreno
Member of the Board of Directors1.8yrs€84.00k0%
$ 0

6.2yrs

Durchschnittliche Betriebszugehörigkeit

63.5yo

Durchschnittliches Alter

Erfahrener Vorstand: PRQRDie Vorstandsmitglieder gelten als erfahren (6.2 Jahre durchschnittliche Amtszeit).